Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial

Trial Profile

Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chiglitazar (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CMAP
  • Sponsors Chipscreen Biosciences
  • Most Recent Events

    • 26 Jun 2023 Results of post-hoc analysis from CMAP and CAMS identifying the subgroup with higher benefits with chiglitazar, using a machine learning algorithm , presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
    • 19 Oct 2021 Results published in the Chipscreen Biosciences Media Release.
    • 19 Oct 2021 According to a Chipscreen Biosciences media release, Bilessglu (Chiglitazar Sodium tablets) has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of Type 2 Diabetes (T2DM). The approval is based on CMAS and CMAP studies.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top